Cellromax Science셀로맥스사이언스
471820 · KOSDAQ · ₩471820 · 셀로맥스사이언스
- Market cap
- ₩45B
- Enterprise value
- ₩39B
- P/E
- 11.8×
- P/B
- 1.0×
- Dividend yield
- 4.7%
- ROE
- 8.1%
- Net margin
- 19.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−48.4% from the high
₩3,410Today: ₩3,915 – ₩4,100₩7,690
Returns
- 1W−1.6%
- 1M−1.6%
- 3M+5.5%
- 6M−24.0%
- YTD−39.0%
- 1Y−22.7%
- Volume today
- 4,577
- 1.3× the 20-day average
- Traded today
- ₩18M
- Listed shares
- 11,302,879
- EPS (12 months)
- ₩337
- Earnings yield 8.5%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 48 of 100 (50 is a normal day for this stock).
- MomentumFlat-1.6% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Cellromax Science stock overview
Cellromax Science (셀로맥스사이언스, KRX: 471820) is listed on KOSDAQ, in the Food & Beverage sector. The company, founded in 2014, develops health functional foods, over-the-counter medicines and cosmetics using naturally derived ingredients sourced through global partnerships. Its shares closed at ₩3,965 on Oct 29, 2026, down 2.46% on the day, giving it a market value of ₩45B.
Key facts
- Market cap
- ₩45B
- Sector
- Food & Beverage
- Latest price change
- −2.46%
- As of
- Oct 29, 2026
- Main business
- The company, founded in 2014, develops health functional foods, over-the-counter medicines and cosmetics using naturally derived ingredients sourced through global partnerships.
Quick answers about Cellromax Science
- What does Cellromax Science do?
- The company, founded in 2014, develops health functional foods, over-the-counter medicines and cosmetics using naturally derived ingredients sourced through global partnerships. It sells mainly through a membership network of pharmacies in South Korea, with products also sold through its own online store and a Hong Kong online shopping platform, and it is preparing to expand into other Asian markets. Manufacturing is outsourced to domestic contract manufacturers.
- What is the market cap of Cellromax Science?
- The market capitalisation of Cellromax Science was ₩45B at the close on Oct 29, 2026.
- Who are the largest shareholders of Cellromax Science?
- According to the latest official filings, the largest reported holders are Seo Jeong-min (71.45%, as of Apr 7, 2026); Moon Min-seon (23.74%, as of Dec 20, 2024); Park Min-jeong (10.21%, as of Jan 27, 2026).
- When is the next earnings report from Cellromax Science?
- Korean companies rarely announce results dates in advance. Based on when Cellromax Science filed the same report in past years, its next 3q results is expected around Nov 21, 2026.
Company profile
The company, founded in 2014, develops health functional foods, over-the-counter medicines and cosmetics using naturally derived ingredients sourced through global partnerships. It sells mainly through a membership network of pharmacies in South Korea, with products also sold through its own online store and a Hong Kong online shopping platform, and it is preparing to expand into other Asian markets. Manufacturing is outsourced to domestic contract manufacturers.
Written by AI from the company's latest annual report.
- Korean name
- 셀로맥스사이언스
- Sector
- Food & Beverage
- Themes
- K-food & ramen
- CEO
- 서정민
- Founded
- Oct 2014
- Listed
- Dec 2024
- Listed shares
- 11,302,879
- Fiscal year ends
- Month 12
- Website
- cellromax.kr/
Similar companies
- Samyang Foods003230 · ₩8.6T₩1,142,000−4.19%
- Orion271560 · ₩4.5T₩112,900+1.26%
- CJ Cheiljedang097950 · ₩2.6T₩171,300+0.88%
- Nongshim004370 · ₩2.4T₩388,000−0.39%
- Otoki007310 · ₩1.3T₩314,500+2.11%
- Hite Jinro000080 · ₩1.1T₩15,600+0.97%
- Lotte Wellfood280360 · ₩1.1T₩117,600+0.68%
- Lotte Chilsung Beverage005300 · ₩899B₩96,900+1.04%
Recent filings
See all- Trust Contract Termination Result ReportOct 23, 2026
- Cash dividend decisionOct 8, 2026
- Interim (Quarterly) Dividend Ex-DateSep 28, 2026
- Decision on Shareholder Register Closure (Record Date) for Interim (Quarterly) DividendSep 10, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: Cellromax Science / 셀로맥스사이언스 / 471820 / KRX:471820
Source: KRX statistical information